Taken together, these findings indicate that rs4917 and rs4918 polymorphisms may play a pivotal role in modulating fetuin-A biology, thereby contributing to their potential as clinically significant genetic determinants in the context of chronic kidney disease and related cardiovascular complications. This evidence concerns the gene AHSG and chronic kidney disease.